402 related articles for article (PubMed ID: 32519753)
21. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
22. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
23. Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection.
Polansky H; Lori G
Int J Antimicrob Agents; 2020 Jun; 55(6):105971. PubMed ID: 32283177
[No Abstract] [Full Text] [Related]
24. A Review of Remdesivir for COVID-19: Data to Date.
Mehta M; Shyh GI
Cardiol Rev; 2020; 28(6):332-334. PubMed ID: 32773440
[TBL] [Abstract][Full Text] [Related]
25. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.
Rizzo E
Naunyn Schmiedebergs Arch Pharmacol; 2020 Jul; 393(7):1153-1156. PubMed ID: 32462282
[TBL] [Abstract][Full Text] [Related]
26. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
27. Metabolomics to Predict Antiviral Drug Efficacy in COVID-19.
Migaud M; Gandotra S; Chand HS; Gillespie MN; Thannickal VJ; Langley RJ
Am J Respir Cell Mol Biol; 2020 Sep; 63(3):396-398. PubMed ID: 32574504
[No Abstract] [Full Text] [Related]
28. Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19.
Cheudjeu A
Life Sci; 2020 Nov; 260():118335. PubMed ID: 32846167
[TBL] [Abstract][Full Text] [Related]
29. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
Wang Y; Chen L
Br J Pharmacol; 2020 Nov; 177(21):4995-4996. PubMed ID: 32424836
[No Abstract] [Full Text] [Related]
30. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulatory and anti-inflammatory potential of crocin in COVID-19 treatment.
Ghasemnejad-Berenji M
J Food Biochem; 2021 May; 45(5):e13718. PubMed ID: 33817822
[TBL] [Abstract][Full Text] [Related]
32. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19.
Berretta AA; Silveira MAD; Cóndor Capcha JM; De Jong D
Biomed Pharmacother; 2020 Nov; 131():110622. PubMed ID: 32890967
[TBL] [Abstract][Full Text] [Related]
33. Macrolide treatment for COVID-19: Will this be the way forward?
Ohe M; Shida H; Jodo S; Kusunoki Y; Seki M; Furuya K; Goudarzi H
Biosci Trends; 2020 May; 14(2):159-160. PubMed ID: 32249257
[TBL] [Abstract][Full Text] [Related]
34. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.
Vankadari N
Int J Antimicrob Agents; 2020 Aug; 56(2):105998. PubMed ID: 32360231
[TBL] [Abstract][Full Text] [Related]
35. Boosting the arsenal against COVID-19 through computational drug repurposing.
Ciliberto G; Cardone L
Drug Discov Today; 2020 Jun; 25(6):946-948. PubMed ID: 32304645
[No Abstract] [Full Text] [Related]
36. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
37. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
38. Famotidine Against SARS-CoV2: A Hope or Hype?
Ghosh R; Chatterjee S; Dubey S; Lavie CJ
Mayo Clin Proc; 2020 Aug; 95(8):1797-1799. PubMed ID: 32753153
[No Abstract] [Full Text] [Related]
39. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Jorgensen SCJ; Kebriaei R; Dresser LD
Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287
[TBL] [Abstract][Full Text] [Related]
40. Natural history of COVID-19 and current knowledge on treatment therapeutic options.
Dos Santos WG
Biomed Pharmacother; 2020 Sep; 129():110493. PubMed ID: 32768971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
